NCT02361112View on ClinicalTrials.gov

Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions
Metastatic Breast Cancer
Interventions
DRUG

pyrotinib combined with capecitabine

Trial Locations (1)

100029

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02361112 - Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter